GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (NAS:BCTX) » Definitions » Receivables Turnover

BriaCell Therapeutics (BriaCell Therapeutics) Receivables Turnover : 0.00 (As of Jan. 2024)


View and export this data going back to . Start your Free Trial

What is BriaCell Therapeutics Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. BriaCell Therapeutics's Revenue for the three months ended in Jan. 2024 was $0.00 Mil. BriaCell Therapeutics's average Accounts Receivable for the three months ended in Jan. 2024 was $0.03 Mil.


BriaCell Therapeutics Receivables Turnover Historical Data

The historical data trend for BriaCell Therapeutics's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics Receivables Turnover Chart

BriaCell Therapeutics Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Receivables Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BriaCell Therapeutics Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Receivables Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BriaCell Therapeutics's Receivables Turnover

For the Biotechnology subindustry, BriaCell Therapeutics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BriaCell Therapeutics's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BriaCell Therapeutics's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where BriaCell Therapeutics's Receivables Turnover falls into.



BriaCell Therapeutics Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

BriaCell Therapeutics's Receivables Turnover for the fiscal year that ended in Jul. 2023 is calculated as

Receivables Turnover (A: Jul. 2023 )
=Revenue / Average Total Inventories
=Revenue (A: Jul. 2023 ) / ((Accounts Receivable (A: Jul. 2022 ) + Accounts Receivable (A: Jul. 2023 )) / count )
=0 / ((0.024 + 0.019) / 2 )
=0 / 0.0215
=N/A

BriaCell Therapeutics's Receivables Turnover for the quarter that ended in Jan. 2024 is calculated as

Receivables Turnover (Q: Jan. 2024 )
=Revenue / Average Total Inventories
=Revenue (Q: Jan. 2024 ) / ((Accounts Receivable (Q: Oct. 2023 ) + Accounts Receivable (Q: Jan. 2024 )) / count )
=0 / ((0.021 + 0.03) / 2 )
=0 / 0.0255
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BriaCell Therapeutics  (NAS:BCTX) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.


BriaCell Therapeutics Receivables Turnover Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


BriaCell Therapeutics (BriaCell Therapeutics) Business Description

Traded in Other Exchanges
Address
235 - 15th Street, Suite 300, West Vancouver, 3rd Floor, Bellevue Centre, Vancouver, BC, CAN, V7T 2X1
BriaCell Therapeutics Corp is an immuno-oncology-focused biotechnology company. The group develops targeted and safe approaches for the management of cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT in metastatic breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for the treatment of advance-stage breast cancer by matching the patient's HLA type.
Executives
Jamieson Bondarenko director 402-1 SCOTT ST.`, TORONTO A6 M5E 1A1
Jane A Gross director 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Rebecca Taub director 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Gadi Levin officer: CFO & Secretary MOSHAV AZRIEL 108, LEV HASHARON L3 4582500
Priore Giuseppe Del officer: Chief Medical Officer 44 WALL STREET, 12TH FLOOR, NEW YORK NY 10005
Williams V. Williams director, officer: President & CEO 620 SOUTH EAGLE ROAD, HAVERTOWN PA 19083
Martin E. Schmieg director 201 S. 25TH STREET, APT. #521, PHILADELPHIA PA 19103
Miguel A. Lopez-lago officer: Chief Scientific Officer 2401 PENNSYLVANIA AVE., APT #12A6, PHILADELPHIA PA 19130
Vaughn C. Embro-pantalony director P.O. BOX 58, 285 SUNSET BLVD, THORNBURY A6 N0H 2P0
Marc Lustig director 4177 ROCKRIDGE ROAD, WEST VANCOUVER A1 V7W 1A3

BriaCell Therapeutics (BriaCell Therapeutics) Headlines

From GuruFocus

BriaCell CEO Letter to Shareholders

By Stock market mentor Stock market mentor 01-24-2023